Acadia Drops Prader-Willi Program Following Late-Stage Trial Failure
Acadia Scraps Prader-Willi Drug After Late-Stage Failure Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential to ease hyperphagia in the rare…
Talent Acquisition Leaders Shift Recruiting Strategy to Emphasize Internal Mobility
Talent Acquisition Leaders Reframe Recruiting, Focus On Internal Mobility Talent acquisition leaders at leading pharma and biotech organizations are leveraging technologies, including automation, to develop internal talent marketplaces and systems that support…
Massachusetts: Fostering Communities of Innovation
Embracing Communities of Innovation: Massachusetts Our strategy to transform patients’ lives has always centered on building state-of-the-art research centers within communities that spark innovation. Massachusetts stands as a global hub…
Cytokinetics Opens Submissions for 8th Annual Communications Grant Program
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program.…
Layoff Tracker: Rome Cuts Small Team During Strategic Review
Layoff Tracker: Rome Trims Already-Small Team Amid Strategic Review 2024 was a tough year for the biopharma industry, with several companies including Bayer, Bristol Myers Squibb and Johnson & Johnson…
20,000+ Takeda Employees Back Four New Global CSR Partnerships in 94 Countries
Employee-led initiative supports global partnerships to build stronger, climate-resilient health systems Takeda (TSE:4502/NYSE:TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR)…
Over One Billion People at Risk Due to Uncontrolled High Blood Pressure
Silent global health crisis threatens lives, driving heart disease, stroke, and kidney failure worldwide The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people…
WuXi Biologics Named to FTSE4Good Index Series for Fifth Year in a Row
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has…
CHMP Recommends EU Approval of Koselugo for Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1
Potential First Approved Treatment in the EU Targeting NF1-Associated Plexiform Neurofibromas koselugo (selumetinib), an oral, selective MEK inhibitor, has been recommended for approval in the European Union (EU) for the treatment…
CHMP Recommends EU Approval of Tezspire for Chronic Rhinosinusitis with Nasal Polyps
CHMP Recommends EU Approval of Tezspire for Chronic Rhinosinusitis with Nasal Polyps AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult…
BlueRock Begins Phase III Trial of Cell Therapy Bemdaneprocel with First Parkinson’s Patient Treated
First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary…
AbbVie’s Entry Marks a New Chapter for Psychedelics
Pharma Giant Expands Into Emerging Psychedelic Therapies With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year.…